The validation of surrogate endpoints in meta-analyses of randomized experiments
From MaRDI portal
Publication:4489920
DOI10.1093/biostatistics/1.1.49zbMath1122.62339OpenAlexW2126133903WikidataQ47671365 ScholiaQ47671365MaRDI QIDQ4489920
Helena Geys, Geert Molenberghs, Marc Buyse, Tomasz Burzykowski, Didier Renard
Publication date: 11 July 2000
Published in: Biostatistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1093/biostatistics/1.1.49
Related Items (34)
Center-within-trial versus trial-level evaluation of surrogate endpoints ⋮ A Shrinkage Approach for Estimating a Treatment Effect Using Intermediate Biomarker Data in Clinical Trials ⋮ Comparing Biomarkers as Principal Surrogate Endpoints ⋮ Meta-analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling ⋮ Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time ⋮ Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints ⋮ Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach ⋮ An efficient algorithm to assess multivariate surrogate endpoints in a causal inference framework ⋮ On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints ⋮ Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials ⋮ Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption ⋮ A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials ⋮ Robust Approach to Combining Multiple Markers to Improve Surrogacy ⋮ Assurance in vaccine efficacy clinical trial design based on immunological responses ⋮ Simplified modeling strategies for surrogate validation with multivariate failure-time data ⋮ Choice of units of analysis and modeling strategies in multilevel hierarchical models ⋮ The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials ⋮ Using earlier measures in a longitudinal sequence as a potential surrogate for a later one ⋮ A Bayesian Approach to Surrogacy Assessment Using Principal Stratification in Clinical Trials ⋮ Advances in medical statistics arising from the AIDS epidemic ⋮ Surrogate Marker Evaluation from an Information Theory Perspective ⋮ Statistical evaluation of surrogate endpoints with examples from cancer clinical trials ⋮ Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics ⋮ Discussion on “Surrogate Measures and Consistent Surrogates” ⋮ Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials ⋮ The Evaluation of Multiple Surrogate Endpoints ⋮ Principal Stratification in Causal Inference ⋮ A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker ⋮ Flexible surrogate marker evaluation from several randomized clinical trials with continuous endpoints, using R and SAS ⋮ On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm ⋮ Exploring and validating surrogate endpoints in colorectal cancer ⋮ Pairwise Fitting of Mixed Models for the Joint Modeling of Multivariate Longitudinal Profiles ⋮ Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials ⋮ Linear increment in efficiency with the inclusion of surrogate endpoint
This page was built for publication: The validation of surrogate endpoints in meta-analyses of randomized experiments
